ABAT | 4-aminobutyrate aminotransferase | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) | Cancer-related genes CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
ADD2 | Adducin 2 (beta) | Cytoskeleton related proteins Predicted intracellular proteins
| | | | | Group enriched |
AHNAK2 | AHNAK nucleoprotein 2 | Cancer-related genes Predicted intracellular proteins
| | | | | Tissue enriched |
AHSG | Alpha-2-HS-glycoprotein | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
AK4 | Adenylate kinase 4 | Enzymes Mitochondrial proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AKR1B1 | Aldo-keto reductase family 1, member B1 (aldose reductase) | Cancer-related genes Enzymes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
ALDH6A1 | Aldehyde dehydrogenase 6 family, member A1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Group enriched |
ALDOA | Aldolase A, fructose-bisphosphate | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
AMPH | Amphiphysin | Cancer-related genes Predicted intracellular proteins
| | | | | Tissue enriched |
ANK2 | Ankyrin 2, neuronal | Cytoskeleton related proteins Disease related genes Plasma proteins Potential drug targets Predicted intracellular proteins Transporters
| | | | | Tissue enhanced |
ANLN | Anillin, actin binding protein | Predicted intracellular proteins
| | | | | Tissue enhanced |
ANPEP | Alanyl (membrane) aminopeptidase | CD markers Enzymes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
ASGR2 | Asialoglycoprotein receptor 2 | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
ASS1 | Argininosuccinate synthase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted intracellular proteins
| | | | | Group enriched |
B3GAT1 | Beta-1,3-glucuronyltransferase 1 | Enzymes Predicted intracellular proteins
| | | | | Tissue enriched |
B4GALNT1 | Beta-1,4-N-acetyl-galactosaminyl transferase 1 | Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
BAG2 | BCL2-associated athanogene 2 | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
BCAS1 | Breast carcinoma amplified sequence 1 | Predicted intracellular proteins
| | | | | Tissue enhanced |
BCL11B | B-cell CLL/lymphoma 11B (zinc finger protein) | Cancer-related genes Plasma proteins Predicted intracellular proteins Transcription factors
| | | | | Tissue enhanced |
BIN1 | Bridging integrator 1 | Disease related genes Predicted intracellular proteins
| | | | | Tissue enriched |
BIN2 | Bridging integrator 2 | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
BPI | Bactericidal/permeability-increasing protein | Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
C1orf116 | Chromosome 1 open reading frame 116 | Predicted intracellular proteins
| | | | | Tissue enhanced |
C3 | Complement component 3 | Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enriched |
C4BPA | Complement component 4 binding protein, alpha | Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
CA1 | Carbonic anhydrase I | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Group enriched |
CA3 | Carbonic anhydrase III, muscle specific | Enzymes FDA approved drug targets Plasma proteins Predicted intracellular proteins
| | | | | Tissue enriched |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CALML4 | Calmodulin-like 4 | Predicted intracellular proteins
| | | | | Tissue enhanced |
CALML5 | Calmodulin-like 5 | Plasma proteins Predicted intracellular proteins RAS pathway related proteins
| | | | | Group enriched |
CAP2 | CAP, adenylate cyclase-associated protein, 2 (yeast) | Cancer-related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
CASC5 | Cancer susceptibility candidate 5 | Cancer-related genes Disease related genes Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
CAV1 | Caveolin 1, caveolae protein, 22kDa | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CAV2 | Caveolin 2 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CBS | Cystathionine-beta-synthase | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
CBS | Cystathionine-beta-synthase | Predicted intracellular proteins
| | | | | Tissue enhanced |
CCR7 | Chemokine (C-C motif) receptor 7 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
CCSAP | Centriole, cilia and spindle-associated protein | Predicted intracellular proteins
| | | | | Tissue enhanced |
CD247 | CD247 molecule | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD37 | CD37 molecule | CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CD3E | CD3e molecule, epsilon (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
CD48 | CD48 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD5 | CD5 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD69 | CD69 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CD79A | CD79a molecule, immunoglobulin-associated alpha | Cancer-related genes CD markers Disease related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CDH15 | Cadherin 15, type 1, M-cadherin (myotubule) | Disease related genes Predicted membrane proteins
| | | | | Tissue enriched |
CDH2 | Cadherin 2, type 1, N-cadherin (neuronal) | CD markers Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |